Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
1. A method of manufacturing a cell therapy product for treating cancer in a patient, the method comprising:
receiving, at a computing device, a cell order request to manufacture the cell therapy product for the patient by processing at least a portion of a tumor or a population of cells obtained from the patient using a multi-step cell expansion process, manufacturing slots for performing the multi-step cell expansion process, and a preliminary schedule of patient treatment events for treating the patient with the cell therapy product, wherein the patient treatment events include infusing the cell therapy product into the patient;
determining and displaying in a scheduling user interface, by the computing device, one or more available manufacturing slots for performing the multi-step cell expansion process based on the preliminary schedule of patient treatment events;
after selection of one of the available manufacturing slots, performing, at a medical facility, a procedure on the patient to obtain the portion of tumor or the population of cells from the patient in accordance with the preliminary schedule of patient treatment events and the selected available manufacturing slot;
generating a container label including a patient-specific identifier and a cell order identifier to be associated with a shipping container containing the portion of tumor or the population of cells;
transferring the portion of tumor or the population of cells to a manufacturing facility corresponding to the selected available manufacturing slot, reading the container label and transmitting a first message indicating a change of custody of biological material comprising the portion of the tumor or the population of cells;
performing a quality check procedure on the tumor or the population of cells and upon determining that the portion of the tumor or the population of cells meets a predetermined quality criteria, generating a manufacturing label, including the patient-specific identifier and the cell order identifier, to be associated with a manufacturing container used in the multi-step cell expansion process; and
initiating, at the manufacturing facility, the multi-step cell expansion process, and transmitting a second message indicating a second change of custody of the biological material based on reading of the manufacturing label,
wherein the manufacturing slots are indicative of availability of equipment and personnel at the manufacturing facility to enable the manufacturing facility to manufacture the cell therapy product.
2. The method of claim 1 , further comprising:
performing quality control assays to determine acceptance parameters at each of a plurality of time points during the multi-step cell expansion process;
determining, during the manufacturing of the cell therapy product, whether the acceptance parameters determined at respective time points meet acceptance criteria associated with the respective time points; and
modifying, by the computing device, a schedule of manufacturing of the cell therapy product, the manufacturing slots, and the preliminary schedule of patient treatment events based on whether the acceptance parameters meet acceptance criteria at each of the respective time points.
3. The method of claim 2 , wherein the determining whether the acceptance parameters meet the acceptance criteria comprises determining the acceptance parameters at the plurality of time points following initiation of the multi-step cell expansion process, the plurality of time points including a first time point and a second time point subsequent to the first time point,
wherein the acceptance parameters comprise one or more of viability, sterility, cell count, mycoplasma count, CD3 count, result of an endotoxin assay, and a result of a Gram stain assay.
4. The method of claim 2 , wherein modifying the preliminary schedule of patient treatment events comprises rescheduling patient treatment events in the preliminary schedule in response to a determination that the acceptance parameters do not meet acceptance criteria at one or more of the plurality of time points.
5. The method of claim 2 , wherein the modifying the preliminary schedule of patient treatment events comprises canceling patient treatment events in the preliminary schedule in response to a determination that the acceptance parameters for the cell therapy product do not meet acceptance criteria at any of the plurality of time points because of contamination.
6. The method of claim 2 , further comprising:
terminating, in response to a determination that the acceptance parameters do not meet acceptance criteria at one or more of the plurality of time points because of contamination, subsequent steps in the multi-step cell expansion process, and
modifying the availability of manufacturing slots.
7. The method of claim 2 , wherein modifying the schedule of manufacturing comprises determining time points among the plurality of time points at which the acceptance parameters do not meet the acceptance criteria, and modifying the schedule of manufacturing of the cell therapy product based on the determined time points.
8. The method of claim 2 , further comprising scheduling a set of dates corresponding to the plurality of time points, including the first and second time points, for determining whether the acceptance parameters meet acceptance criteria during the multi-step cell expansion process depending on a cell expansion technique used in the multi-step cell expansion process and when the cell order request is received.
9. The method of claim 2 , further comprising, upon determining that the acceptance parameters at the first time point do not meet acceptance criteria at the first time point, determining whether re-performing of steps of the multi-step cell expansion process subsequent to the first time point is feasible, and
upon determining that the re-performing of the steps is feasible, estimating, by the computing device, a time of completion of the multi-step cell expansion process following the re-performing of the steps by determining a time needed for completing manufacturing from the first time point based on one or both of the acceptance parameters at the second time point and the acceptance parameters associated with a population of cells used for re-performing steps of the multi-step cell expansion process from the first time point onwards.
10. The method of claim 9 , further comprising: upon determination that the acceptance parameters at the first time point do not meet corresponding acceptance criteria, and in response to a determination that re-performing of steps of the multi-step cell expansion process from the first time point is feasible, generating, by the computing device, an updated cell order identifier associated with the cell order request and associating the updated cell order identifier with the patient-specific identifier,
wherein the cell order request to manufacture the cell therapy product is received from a hospital-side computer subsystem, and the method further comprises transmitting the patient-specific identifier, the updated cell order identifier and the estimated time of completion of the expansion of the cell therapy product to the hospital-side computer subsystem.
11. The method of claim 10 , further comprising:
generating, by the computing device, an updated schedule for shipping and logistics events associated with patient treatment events in the preliminary schedule of patient treatment events based on the modifying of the preliminary schedule of patient treatment events;
transmitting the updated schedule of shipping and logistics events associated the patient-specific identifier and the updated cell order identifier to a logistics computer subsystem;
associating, by the computing device, with the patient-specific identifier at each time point at which determination of whether the acceptance parameters meet acceptance criteria is made, the updated cell order identifier including fields corresponding to each respective time point and a result of the determination; and
in response to a determination that re-performing of manufacturing of the cell therapy product is not possible, canceling, by the computing device, patient treatment events in the preliminary schedule of patient treatment events scheduled subsequent to the second time point and transmitting cancellation of patient treatment events to a hospital-side computer subsystem and a logistics computer subsystem.
12. The method of claim 9 , further comprising, in response to a determination that re-performing of manufacturing of the cell therapy product is not feasible, terminating manufacturing of the cell therapy product and disassociating the patient-specific identifier from the cell order identifier.
13. The method of claim 1 , further comprising:
completing the manufacturing of the cell therapy product; and
transferring the cell therapy product to the medical facility.
14. The method of claim 1 , further comprising, upon receiving the cell order request, generating, by the computing device, the cell order identifier and the patient-specific identifier, wherein the cell order identifier and the patient-specific identifier define the chain of custody and a chain of identity for the biological material.
15. The method of claim 14 , wherein the cell order request to manufacture the cell therapy product is received from a hospital-side computer subsystem, and wherein the method further comprises transmitting, upon receiving the cell order request, a confirmation, including one or both of the patient-specific identifier and the cell order identifier, to the hospital-side computer subsystem indicating that the cell order request associated with the patient has been received.
16. The method of claim 15 , further comprising transmitting, upon modifying the preliminary schedule of patient treatment events, to a hospital-side computer subsystem an updated preliminary schedule of patient treatment events associated with the patient-specific identifier.
17. The method of claim 14 , wherein the container label further comprises the selected available manufacturing slot and the manufacturing facility.
18. The method of claim 14 , further comprising:
transmitting, to a logistics computer subsystem, a pick-up order associated with the patient-specific identifier based on an estimated time of completion of manufacturing of the cell therapy product; and
transmitting, to a hospital-side computer subsystem, a schedule for the patient treatment events associated with the patient-specific identifier based on the estimated time of completion of manufacturing of the cell therapy product.
19. The method of claim 1 , wherein the manufacturing label further comprises information associated with a time point among a plurality of time points associated with the multi-step cell expansion process when the manufacturing label is generated, a container-identifying graphical identification code, and a batch record identifier.
20. The method of claim 1 , wherein the schedule of patient treatment events includes one or more of an inpatient stay time period, resection date, lymphodepletion date, infusion date for infusing the patient with the cell therapy product and IL-2 treatment date.
21. A method of treating the patient with the cell therapy product obtained by the method of claim 1 in accordance with the modified preliminary schedule of patient treatment events.